Adimmune, your trusted partner to global market
We tailor our services to customers’ needs and offer solutions for various scales, phases, and timelines. We are one of the key suppliers of high-quality vaccines and biologics around the world.
View All
Support Resilient
Supply for Vaccines
We engage with the WHO Pandemic Influenza Preparedness Framework to foster the development and access to vaccines. Recognized by US FDA and the EU, we tackle health challenges by leveraging our high standards of quality.
19 Dec. 2025
Adimmune Celebrates 60th Anniversary with Community-Focused Charity Event
Adimmune Corporation (TWSE: 4142) marked its 60th anniversary yesterday with a charity Christmas fair held in Tanzi District, Taichung, reaffirming the Company’s long-standing commitment to community engagement, public health, and sustainable development.
17 Dec. 2025
Adimmune and Enimmune Receive Gold Award for Corporate Epidemic Prevention; Recognized Among Top 10 Vaccine News of 2025
Adimmune Corporation (TWSE: 4142) today announced that both Adimmune and its subsidiary, Enimmune Corp. (TWSE: 6564), have been honored with the Gold Award for Corporate Epidemic Prevention, and recognized among the Top 10 Vaccine News of 2025.
21 Oct. 2025
Adimmune Group Vaccines Listed in WHO Full Vaccine Product List
Adimmune Corporation (TWSE:4142) today announced that three of its vaccines—the seasonal influenza vaccine, tetanus toxoid vaccine, and the enterovirus 71 (EV71) vaccine developed by its subsidiary Enimmune—are now officially listed in the World Health Organization (WHO) Full Vaccine Product List published in September. Inclusion in the WHO list signifies that Adimmune has entered the global public health supply chain, marking a significant milestone for Taiwan’s vaccine industry as its quality and manufacturing capabilities gain recognition from the global health community.
